Evotec SE
EVO evidence brief
What we can confirm
- Market Cap:
- $614.8M
What it means
What to watch
Prepared research question
What matters most for EVO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · EVO
Evotec SE is a German drug discovery and development company that operates a biologics CDMO subsidiary and partners with government and industry to advance preclinical and clinical programs.
Key risk: Revenue guidance cut
Market Cap
$614.8M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Evotec SE is a German drug discovery and development company that operates a biologics CDMO subsidiary and partners with government and industry to advance preclinical and clinical programs.
- Evotec's subsidiary Just – Evotec Biologics initiated a Phase 1 trial for JST-018, an orthopoxvirus antibody cocktail developed under the U.S. Department of War's Accelerated Antibodies Program [news · published 2026-09-09].
- Evotec participated in a €40M seed financing round for Aptadir Therapeutics, alongside 4BIO Capital and other investors, to advance demethylating RNA inhibitors [news · published 2026-09-29].
- Evotec nominated a preclinical development candidate from its multi-target drug discovery alliance with Almirall focused on medical dermatology [news · published 2026-05-13].
- Evotec revised its FY26 revenue outlook from €700M-€780M to approximately €570M-€610M, with H1 2026 revenue of about €300.1M [news · published 2026-07-13].
- For the first nine months of 2025, Evotec reported group revenues of €535.1M, with its Just – Evotec Biologics segment growing 11.3% year-over-year [news · published 2025-11-05].
What works
- Just – Evotec Biologics (JEB) segment showed above-expectation growth of +11.3% in the first nine months of 2025, indicating strong demand for its biologics CDMO services [news · published 2025-11-05].
- Evotec secured a U.S. Department of War contract for biodefense antibody development, leading to a Phase 1 trial for JST-018, demonstrating government partnership capability [news · published 2026-09-09].
- Evotec's participation in the €40M seed round for Aptadir Therapeutics shows its ability to leverage its EXTEND venture platform to support early-stage RNA therapeutics [news · published 2026-09-29].
What to weigh
- Evotec's Discovery & Preclinical Development segment experienced a 12.3% revenue decline in the first nine months of 2025, reflecting soft demand in that area [news · published 2025-11-05].
- Evotec significantly lowered its full-year 2026 revenue guidance from €700M-€780M to approximately €570M-€610M, indicating a substantial downward revision in expectations [news · published 2026-07-13].
- Group revenues for the first nine months of 2025 decreased 7.1% year-over-year, suggesting overall top-line pressure [news · published 2025-11-05].
From the filings
Quoted directly from source documents.
Evotec's subsidiary initiated a Phase 1 trial for orthopoxvirus antibodies under a U.S. Department of War program.
“Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced the initiation of a Phase 1 clinical trial evaluating JST-018, a cocktail of investigational monoclonal antibodies targeting orthopoxviruses, developed by its biologics CDMO subsidiary Just – Evotec Biologics under the U.S. Department of War's Accelerated Antibodies Program.”
News · September 9, 2026
Evotec participated in a €40M seed financing for Aptadir Therapeutics.
“Seed led by 4BIO Capital with follow-on participation from the company's original pre-seed investor EXTEND (CDP Venture Capital SGR, Angelini Ventures and Evotec SE)”
News · September 29, 2026
Evotec nominated a preclinical candidate from its Almirall alliance.
“Evotec SE (NASDAQ:EVO) announced the nomination of a small molecule preclinical development candidate from its multi-target drug discovery alliance with Almirall focused on medical dermatology.”
News · May 13, 2026
Evotec revised its FY26 revenue outlook downward.
“Evotec Now Expects FY26 Revenue From €700M - €780M To ~€570M - €610M, Expects H1 Revenue Of ~€300.1M”
News · July 13, 2026
Catalyst timeline
- 2026-06-23 · Phase 1 Start for JST-018 — Phase 1, randomized, double-blind, placebo-controlled, single ascending dose study to assess safety, tolerability, and pharmacokinetics of JST-018 in healthy adults.
Risks & what to watch (3)›
Key risks
- Revenue guidance cut — FY26 revenue outlook slashed from €700M-€780M to ~€570M-€610M, indicating significant operational or market headwinds [news · published 2026-07-13].
- Discovery segment decline — Discovery & Preclinical Development segment revenue fell 12.3% in 9M 2025, reflecting sustained soft demand [news · published 2025-11-05].
- Overall revenue contraction — Group revenues decreased 7.1% year-over-year in 9M 2025, suggesting broad top-line pressure [news · published 2025-11-05].
What to watch
- Phase 1 safety and pharmacokinetic data from the JST-018 orthopoxvirus antibody trial, expected to read out in 2027 [news · published 2026-09-09].
- Evotec's full-year 2026 financial results and whether the revised revenue guidance of ~€570M-€610M is achieved [news · published 2026-07-13].
- Progress of the preclinical candidate nominated from the Almirall alliance toward clinical development [news · published 2026-05-13].
- Further developments from Aptadir Therapeutics' demethylating RNA inhibitor program, supported by Evotec's EXTEND venture [news · published 2026-09-29].
Sources: Catalysts · Competitor trials · News · Generated October 5, 2026 · How we verify sources →
Run Evotec SE through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Evotec SE facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
46
Total value held
$20.2M
| Holder | Shares | Value |
|---|---|---|
| mubadala investment co pjsc | 4,597,701 | $11.5M |
| dcf advisers, llc | 1,065,274 | $2.7M |
| wcm investment management, llc | 627,260 | $1.5M |
| abc arbitrage sa | 509,050 | $1.3M |
| optiver holding b.v. | 283,576 | $709K |
| morgan stanley | 259,744 | $649K |
| lpl financial llc | 122,346 | $306K |
| envestnet asset management inc | 119,409 | $299K |
| millennium management llc | 99,568 | $249K |
| citadel advisors llc | 87,180 | $218K |
Showing top 10 of 46 institutional holders of Evotec SE. Open the full 13F history after sign-in.
Short Interest
as of Apr 24, 2026- % of float
- 0.1%
- Days to cover
- 2.7
- Shares short
- 349,478
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
EVO short interestGovernance
Frequently asked questions
What is the AI investment thesis for Evotec SE?
Evotec SE is a German drug discovery and development company that operates a biologics CDMO subsidiary and partners with government and industry to advance preclinical and clinical programs.
Who is the CEO of Evotec SE?
Dr. Christian Wojczewski Ph.D. is the chief executive officer of Evotec SE (EVO).
Where is Evotec SE headquartered?
Evotec SE (EVO) is headquartered in Hamburg, Germany.
What therapeutic areas does Evotec SE focus on?
Evotec SE develops therapies across Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.